These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11714470)

  • 1. [May drugs be a cost-effective investment in Spanish health system?].
    Soto J; Olivella P
    Med Clin (Barc); 2001 Nov; 117(16):622-4. PubMed ID: 11714470
    [No Abstract]   [Full Text] [Related]  

  • 2. An Italian perspective: studying the cost-effectiveness of sofosbuvir before completion of national price negotiations.
    Messori A; Maratea D; Fadda V; Gatto R; Trippoli S
    Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):813-4. PubMed ID: 24901827
    [No Abstract]   [Full Text] [Related]  

  • 3. [New drugs in Spain -- when are they to be considered cost-effective alternatives and profitable investments for the National Health System? ].
    Soto Alvarez J
    Farm Hosp; 2004; 28(4):299-304. PubMed ID: 15369442
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceutical economy and the economic assessment of drugs in France.
    le Pen C
    Soc Sci Med; 1997 Aug; 45(4):635-43. PubMed ID: 9226787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The need for joint evaluation of pharmaceutical expenditure and the health outcomes obtained].
    Soto Álvarez J
    Gac Sanit; 2011; 25(3):257. PubMed ID: 21459490
    [No Abstract]   [Full Text] [Related]  

  • 6. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 7. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The budget control function of the Drug Reimbursement System].
    Vooren PH
    Ned Tijdschr Geneeskd; 2002 Nov; 146(47):2264-5. PubMed ID: 12481525
    [No Abstract]   [Full Text] [Related]  

  • 9. Implementing pharmacoeconomic guidelines in Latin America: lessons learned.
    Augustovski F; Melendez G; Lemgruber A; Drummond M
    Value Health; 2011; 14(5 Suppl 1):S3-7. PubMed ID: 21839895
    [No Abstract]   [Full Text] [Related]  

  • 10. [Co-payment and the hospital pharmacy].
    Lamas Díaz MJ; Delgado Sánchez O; Poveda Andrés JL
    Farm Hosp; 2013; 37(5):345-7. PubMed ID: 24128094
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain.
    Grau S; Alvarez-Lerma F; del Castillo A; Neipp R; Rubio-Terrés C
    J Chemother; 2005 Apr; 17(2):203-11. PubMed ID: 15920907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs, money and society (Part II).
    Walley T
    Br J Clin Pharmacol; 2010 Sep; 70(3):342-5. PubMed ID: 20716232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Separate pharmaceutical budgets: skating on thin ice].
    Egberts AC; de Boer A
    Ned Tijdschr Geneeskd; 2010; 154(51-52):A3004. PubMed ID: 21211087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Health economics, pharmacoeconomics and prescriptions in dermatology].
    Berdeaux G
    Ann Dermatol Venereol; 2000 Mar; 127(3):324-8. PubMed ID: 10804314
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cost-effectiveness of buccal midazolam in the treatment of prolonged convulsive seizures in the outpatient setting in Spain].
    Raspall-Chaure M; Martinez-Bermejo A; Sanchez-Carpintero R; Ruiz-Falco Rojas ML; Verdu-Perez A; Smeyers-Dura P; Camino-Leon R; Sanmarti FX; Santos-Borbujo J; Pico G; Blanco-Barca O; Cebollero MA
    Rev Neurol; 2014 Jun; 58(11):481-6. PubMed ID: 24861222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomics: NICE's approach to decision-making.
    Rawlins M; Barnett D; Stevens A
    Br J Clin Pharmacol; 2010 Sep; 70(3):346-9. PubMed ID: 20716233
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective].
    De Lossada A; Oteo-Álvaro Á; Giménez S; Oyagüez I; Rejas J
    Semergen; 2016; 42(4):235-43. PubMed ID: 26006311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics: basic concepts and terminology.
    Walley T; Haycox A
    Br J Clin Pharmacol; 1997 Apr; 43(4):343-8. PubMed ID: 9146844
    [No Abstract]   [Full Text] [Related]  

  • 19. The high cost of medicines in Ireland. Is it time to change the pricing mechanism?
    Tilson L; McGowan B; Bennett K; Barry M
    Eur J Health Econ; 2004 Dec; 5(4):341-4. PubMed ID: 15452737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings.
    de Salas-Cansado M; Pérez C; Saldaña MT; Navarro A; González-Gómez FJ; Ruiz L; Rejas J
    Prim Care Diabetes; 2012 Dec; 6(4):303-12. PubMed ID: 22595032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.